Screener
Corcept Therapeutics CORT Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $112.29M+9.3% | $109.99M+22.5% | $121.75M-5.4% | $125.14M-8.9% | $102.75M-20.1% | ||
| $197.16M-17.7% | $229.45M-1.5% | $251.66M-1.6% | $296.55M+22.0% | $239.48M-30.5% | ||
| $76.92M+19.1% | $39.07M-36.8% | $59.79M+10.8% | $69.63M+16.6% | $64.57M+19.9% | ||
| $18.96M+137% | $14.51M+1,144% | $11.09M+210% | $12M+54.6% | $7.99M-5.4% | ||
| $439.68M-0.8% | $426.03M-2.8% | $485.46M+2.9% | $541.13M+15.9% | $443.11M-21.0% | ||
| $5.13M+119% | $3.17M+24.7% | $1.89M-29.7% | $2.09M-28.5% | $2.35M+59.5% | ||
| $888.7M+10.8% | $814.88M-3.7% | $836.65M-0.5% | $823.61M+5.0% | $801.72M+12.2% | ||
| $14.91M-36.6% | $33.31M+19.2% | $40.44M+163% | $34.45M+85.4% | $23.53M+20.7% | ||
| $153.8M+6.3% | $149.19M+4.3% | $166.09M+18.0% | $172.27M+36.5% | $144.66M+43.6% | ||
| $182.93M+10.2% | $176.89M+8.4% | $188.85M+17.3% | $191.71M+31.8% | $165.93M+40.2% | ||
| $142K+2.9% | $141K+2.9% | $140K+2.9% | $139K+3.0% | $138K+3.0% | ||
| $654.61M+9.2% | $611.63M+8.4% | $643.39M+18.3% | $619.1M+20.7% | $599.43M+28.7% | ||
| $705.78M+11.0% | $637.99M-6.6% | $647.81M-4.7% | $631.9M-1.1% | $635.79M+6.6% | ||
| $888.7M+10.8% | $814.88M-3.7% | $836.65M-0.5% | $823.61M+5.0% | $801.72M+12.2% |
FAQ
- What are Corcept Therapeutics's total assets?
- Corcept Therapeutics (CORT) holds $888.7M in total assets, up 10.8% year over year.
- How much debt does Corcept Therapeutics have?
- Corcept Therapeutics carries $9.4M in total debt against $705.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Corcept Therapeutics have?
- Corcept Therapeutics holds $112.3M in cash and equivalents.
- Can Corcept Therapeutics cover its short-term obligations?
- Its current ratio is 2.86 — current assets exceed current liabilities.
- Where does Corcept Therapeutics's balance sheet data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
